Cardiovascular diseases(CVDs)remain the leading cause of morbidity and mortality worldwide,necessitating innovative diagnostic and prognostic strategies.Traditional biomarkers like C-reactive protein,uric acid,troponi...Cardiovascular diseases(CVDs)remain the leading cause of morbidity and mortality worldwide,necessitating innovative diagnostic and prognostic strategies.Traditional biomarkers like C-reactive protein,uric acid,troponin,and natriuretic peptides play crucial roles in CVD management,yet they are often limited by sensitivity and specificity constraints.This narrative review critically examines the emerging landscape of cardiac biomarkers and advocates for a multiple-marker approach to enhance early detection,prognosis,and risk stratification of CVD.In recent years,several novel biomarkers have shown promise in revolutionizing CVD diagnostics.Gamma-glutamyltransferase,microRNAs,endothelial microparticles,placental growth factor,trimethylamine N-oxide,retinol-binding protein 4,copeptin,heart-type fatty acid-binding protein,galectin-3,growth differentiation factor-15,soluble suppression of tumorigenicity 2,fibroblast growth factor 23,and adrenomedullin have emerged as significant indicators of CV health.These biomarkers provide insights into various pathophysiological processes,such as oxidative stress,endothelial dysfunction,inflammation,metabolic disturbances,and myocardial injury.The integration of these novel biomarkers with traditional ones offers a more comprehensive understanding of CVD mechanisms.This multiple-marker approach can improve diagnostic accuracy,allowing for better risk stratification and more personalized treatment strategies.This review underscores the need for continued research to validate the clinical utility of these biomarkers and their potential incorporation into routine clinical practice.By leveraging the strengths of both traditional and novel biomarkers,precise therapeutic plans can be developed,thereby improving the management and prognosis of patients with CVDs.The ongoing exploration and validation of these biomarkers are crucial for advancing CV care and addressing the limitations of current diagnostic tools.展开更多
Hypoplastic left heart syndrome is a severe congenital defect involving underdeveloped left-sided cardiac structures,leading to significant mortality and morbidity.Prenatal diagnosis using fetal ultrasound and echocar...Hypoplastic left heart syndrome is a severe congenital defect involving underdeveloped left-sided cardiac structures,leading to significant mortality and morbidity.Prenatal diagnosis using fetal ultrasound and echocardiography enables early detection,family counseling,and improved clinical decision-making.Advanced prenatal interventions,such as fetal aortic valvuloplasty and atrial septostomy,show promise but require careful patient selection.A multidisciplinary approach involving obstetricians,neonatologists,and pediatric cardiologists is vital for effective management.Future directions include refining imaging techniques,such as three-dimensional ultrasound,cardiovascular magnetic resonance imaging,and exploring bioengineering solutions,stem cell therapies,and genetic research.These advancements aim to improve therapeutic options and address current limitations,including transplant scarcity and postoperative complications.Although surgical innovations have improved survival rates,challenges remain,including neurological risks and long-term hemodynamic issues.Ongoing research and technological advancements are essential to enhance outcomes and quality of life for hypoplastic left heart syndrome patients.展开更多
文摘Cardiovascular diseases(CVDs)remain the leading cause of morbidity and mortality worldwide,necessitating innovative diagnostic and prognostic strategies.Traditional biomarkers like C-reactive protein,uric acid,troponin,and natriuretic peptides play crucial roles in CVD management,yet they are often limited by sensitivity and specificity constraints.This narrative review critically examines the emerging landscape of cardiac biomarkers and advocates for a multiple-marker approach to enhance early detection,prognosis,and risk stratification of CVD.In recent years,several novel biomarkers have shown promise in revolutionizing CVD diagnostics.Gamma-glutamyltransferase,microRNAs,endothelial microparticles,placental growth factor,trimethylamine N-oxide,retinol-binding protein 4,copeptin,heart-type fatty acid-binding protein,galectin-3,growth differentiation factor-15,soluble suppression of tumorigenicity 2,fibroblast growth factor 23,and adrenomedullin have emerged as significant indicators of CV health.These biomarkers provide insights into various pathophysiological processes,such as oxidative stress,endothelial dysfunction,inflammation,metabolic disturbances,and myocardial injury.The integration of these novel biomarkers with traditional ones offers a more comprehensive understanding of CVD mechanisms.This multiple-marker approach can improve diagnostic accuracy,allowing for better risk stratification and more personalized treatment strategies.This review underscores the need for continued research to validate the clinical utility of these biomarkers and their potential incorporation into routine clinical practice.By leveraging the strengths of both traditional and novel biomarkers,precise therapeutic plans can be developed,thereby improving the management and prognosis of patients with CVDs.The ongoing exploration and validation of these biomarkers are crucial for advancing CV care and addressing the limitations of current diagnostic tools.
文摘Hypoplastic left heart syndrome is a severe congenital defect involving underdeveloped left-sided cardiac structures,leading to significant mortality and morbidity.Prenatal diagnosis using fetal ultrasound and echocardiography enables early detection,family counseling,and improved clinical decision-making.Advanced prenatal interventions,such as fetal aortic valvuloplasty and atrial septostomy,show promise but require careful patient selection.A multidisciplinary approach involving obstetricians,neonatologists,and pediatric cardiologists is vital for effective management.Future directions include refining imaging techniques,such as three-dimensional ultrasound,cardiovascular magnetic resonance imaging,and exploring bioengineering solutions,stem cell therapies,and genetic research.These advancements aim to improve therapeutic options and address current limitations,including transplant scarcity and postoperative complications.Although surgical innovations have improved survival rates,challenges remain,including neurological risks and long-term hemodynamic issues.Ongoing research and technological advancements are essential to enhance outcomes and quality of life for hypoplastic left heart syndrome patients.
